Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Discovery
Sponsor : SBIR Grant
Deal Size : $1.0 million
Deal Type : Funding
Details : The funding will be used develop and apply machine learning (ML) tools to explore new areas of chemistry, with the ultimate aim of identifying treatments that target novel or multiple aspects of complex neuropsychiatric disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 09, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Discovery
Sponsor : SBIR Grant
Deal Size : $1.0 million
Deal Type : Funding
Lead Product(s) : KAR-501
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Karuna Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics
Details : The agreement, allowed Karuna to leverage Psychogenics proprietary screening platforms, which utilize computer vision and machine learning to identify and evaluate new drug candidates including KAR-501 to further its pipeline of differentiated neuropsych...
Product Name : KAR-501
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 10, 2022
Lead Product(s) : KAR-501
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Karuna Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration